《国家食品药品监管总局办公厅关于修订他汀类药品说明书的通知》(食药监办药化管[2013]90号)中说明[1],为保障公众用药安全,根据国家食品药品监督管理总局监测评价结果,决定对他汀类药品说明书【不良反应】、【药物相互作用】项进行修订,在【不良反应】项下适当位置增加的内容中第一条是:他汀类药品的上市后监测中有高血糖反应、糖耐量异常、糖化血红蛋白水平升高、新发糖尿病、血糖控制恶化的报告,部分他汀类药品亦有低血糖反应的报告。而在这之前,美国、加拿 In the Notice of the General Office of the State Food and Drug Administration on Revision of Statutory Drugs Specifications (CFDA [1998] No.90), in order to ensure public safety of drugs, according to the instructions of the State Food and Drug Administration Monitor the evaluation results, decided to statutory drug specification “adverse reactions”, “drug interactions” item was revised in the appropriate place under the adverse reactions added content is: statins listed after the monitoring There are reports of hyperglycemic reactions, impaired glucose tolerance, elevated levels of HbA1c, new-onset diabetes, and worsening glycemic control. Some statins also report hypoglycemic reactions. Prior to this, the United States, Canada